MedTrace Logo

2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma

NCT06492460 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 422

Last updated 2025-08-14

No results posted yet for this study

Summary

The main objective of this trial was to determine the value of 2 courses of cisplatin concurrent chemotherapy in postoperative adjuvant radiotherapy for high-risk head and neck squamous cell carcinoma.

Conditions

  • Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG

Drug：Cisplatin

Concurrent Cisplatin chemotherapy (100 mg/m2 intravenous injection,once every 3 weeks, twice in total, on days 1 and 22) will be given plus intensity modulated radiotherapy

Sponsors & Collaborators

  • Hunan Cancer Hospital

    collaborator OTHER

  • Guilin Medical University, China

    collaborator OTHER

  • Jiangsu Cancer Institute & Hospital

    collaborator OTHER

  • Xiangya Hospital of Central South University

    collaborator OTHER

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Lei Chen, M.D · Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-20
Primary Completion
2029-09-20
Completion
2033-07-17

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06492460 on ClinicalTrials.gov